nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—FMO1—forebrain—attention deficit hyperactivity disorder	0.03	0.169	CbGeAlD
Cevimeline—CHRM1—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0198	0.0241	CbGpPWpGaD
Cevimeline—CHRM3—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0197	0.024	CbGpPWpGaD
Cevimeline—CHRM1—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.017	0.0207	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.0169	0.0206	CbGpPWpGaD
Cevimeline—FMO1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.0169	0.0205	CbGpPWpGaD
Cevimeline—CHRM1—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.0166	0.0202	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.0166	0.0202	CbGpPWpGaD
Cevimeline—FMO1—nervous system—attention deficit hyperactivity disorder	0.0163	0.0915	CbGeAlD
Cevimeline—FMO1—central nervous system—attention deficit hyperactivity disorder	0.0157	0.0881	CbGeAlD
Cevimeline—CHRM1—forebrain—attention deficit hyperactivity disorder	0.0138	0.0774	CbGeAlD
Cevimeline—FMO1—brain—attention deficit hyperactivity disorder	0.0124	0.0699	CbGeAlD
Cevimeline—CHRM3—forebrain—attention deficit hyperactivity disorder	0.0123	0.0693	CbGeAlD
Cevimeline—CHRM1—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.012	0.0146	CbGpPWpGaD
Cevimeline—CHRM3—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.012	0.0145	CbGpPWpGaD
Cevimeline—CHRM1—cardiovascular system—attention deficit hyperactivity disorder	0.0116	0.0654	CbGeAlD
Cevimeline—CHRM1—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0115	0.014	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0115	0.014	CbGpPWpGaD
Cevimeline—CHRM1—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.0111	0.0136	CbGpPWpGaD
Cevimeline—CHRM3—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.0111	0.0135	CbGpPWpGaD
Cevimeline—CHRM1—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0108	0.0131	CbGpPWpGaD
Cevimeline—CHRM3—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0108	0.0131	CbGpPWpGaD
Cevimeline—CHRM1—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.0106	0.0129	CbGpPWpGaD
Cevimeline—CHRM3—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.0106	0.0129	CbGpPWpGaD
Cevimeline—CHRM1—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.0105	0.0127	CbGpPWpGaD
Cevimeline—CHRM3—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.0104	0.0127	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of insulin secretion—ADRA2C—attention deficit hyperactivity disorder	0.0102	0.0124	CbGpPWpGaD
Cevimeline—CHRM1—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.0101	0.0123	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.01	0.0122	CbGpPWpGaD
Cevimeline—CHRM1—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.00976	0.0119	CbGpPWpGaD
Cevimeline—CHRM3—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.00973	0.0118	CbGpPWpGaD
Cevimeline—CHRM1—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.00937	0.0114	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.00934	0.0114	CbGpPWpGaD
Cevimeline—CHRM1—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.00907	0.011	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.00904	0.011	CbGpPWpGaD
Cevimeline—FMO1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00903	0.011	CbGpPWpGaD
Cevimeline—FMO1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00897	0.0109	CbGpPWpGaD
Cevimeline—CHRM1—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00892	0.0108	CbGpPWpGaD
Cevimeline—FMO1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00891	0.0108	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00889	0.0108	CbGpPWpGaD
Cevimeline—CHRM1—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00881	0.0107	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00878	0.0107	CbGpPWpGaD
Cevimeline—CHRM1—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00821	0.00998	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00818	0.00995	CbGpPWpGaD
Cevimeline—CHRM3—Integration of energy metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00804	0.00978	CbGpPWpGaD
Cevimeline—CHRM1—nervous system—attention deficit hyperactivity disorder	0.00747	0.042	CbGeAlD
Cevimeline—CHRM1—central nervous system—attention deficit hyperactivity disorder	0.0072	0.0404	CbGeAlD
Cevimeline—CHRM3—Regulation of insulin secretion—CACNB2—attention deficit hyperactivity disorder	0.00706	0.00858	CbGpPWpGaD
Cevimeline—CHRM1—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00684	0.00832	CbGpPWpGaD
Cevimeline—CHRM3—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00682	0.00829	CbGpPWpGaD
Cevimeline—CHRM3—nervous system—attention deficit hyperactivity disorder	0.00669	0.0376	CbGeAlD
Cevimeline—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.00666	0.0374	CbGeAlD
Cevimeline—CHRM3—Regulation of insulin secretion—CACNA1C—attention deficit hyperactivity disorder	0.00645	0.00785	CbGpPWpGaD
Cevimeline—CHRM3—central nervous system—attention deficit hyperactivity disorder	0.00644	0.0362	CbGeAlD
Cevimeline—CHRM1—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00575	0.00699	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00573	0.00697	CbGpPWpGaD
Cevimeline—CHRM1—brain—attention deficit hyperactivity disorder	0.00571	0.0321	CbGeAlD
Cevimeline—CHRM3—Regulation of insulin secretion—SNAP25—attention deficit hyperactivity disorder	0.00564	0.00686	CbGpPWpGaD
Cevimeline—CHRM3—Integration of energy metabolism—CACNB2—attention deficit hyperactivity disorder	0.00555	0.00675	CbGpPWpGaD
Cevimeline—CYP2D6—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00554	0.00674	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of insulin secretion—ADRA2A—attention deficit hyperactivity disorder	0.00537	0.00653	CbGpPWpGaD
Cevimeline—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00535	0.0065	CbGpPWpGaD
Cevimeline—CHRM3—brain—attention deficit hyperactivity disorder	0.00511	0.0287	CbGeAlD
Cevimeline—CHRM3—Integration of energy metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00507	0.00617	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.00478	0.00581	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.00464	0.00564	CbGpPWpGaD
Cevimeline—CHRM3—Integration of energy metabolism—SNAP25—attention deficit hyperactivity disorder	0.00444	0.00539	CbGpPWpGaD
Cevimeline—CHRM3—Integration of energy metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00422	0.00514	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.0039	0.00474	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00389	0.00473	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00382	0.00464	CbGpPWpGaD
Cevimeline—CHRM1—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00382	0.00464	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00381	0.00463	CbGpPWpGaD
Cevimeline—CHRM3—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00381	0.00463	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00379	0.00461	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00378	0.0046	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00369	0.00449	CbGpPWpGaD
Cevimeline—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00367	0.0207	CbGeAlD
Cevimeline—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.00362	0.0203	CbGeAlD
Cevimeline—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00354	0.0199	CbGeAlD
Cevimeline—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.00348	0.0196	CbGeAlD
Cevimeline—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.0034	0.0191	CbGeAlD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00334	0.00406	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00333	0.00405	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—TPH2—attention deficit hyperactivity disorder	0.00329	0.004	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00327	0.00398	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00326	0.00397	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00303	0.00368	CbGpPWpGaD
Cevimeline—CYP2D6—brain—attention deficit hyperactivity disorder	0.00276	0.0155	CbGeAlD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00265	0.00322	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00264	0.00321	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—SLC6A4—attention deficit hyperactivity disorder	0.00263	0.00319	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.00263	0.00319	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00255	0.0031	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00255	0.0031	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.00254	0.00309	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00254	0.00309	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00253	0.00308	CbGpPWpGaD
Cevimeline—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00251	0.00306	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00251	0.00305	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00249	0.00303	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00248	0.00302	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	0.00247	0.003	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00233	0.00284	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00231	0.00281	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00231	0.00281	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—DRD2—attention deficit hyperactivity disorder	0.0023	0.0028	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00227	0.00276	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00226	0.00275	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00215	0.00262	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00214	0.00261	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00214	0.00261	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00214	0.0026	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00208	0.00253	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00208	0.00253	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00205	0.00249	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00204	0.00248	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00204	0.00248	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00202	0.00246	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00202	0.00245	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00198	0.00241	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00198	0.0024	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00195	0.00237	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00194	0.00236	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00194	0.00236	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00188	0.00229	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00188	0.00228	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00184	0.00224	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00184	0.00223	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00178	0.00217	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00178	0.00216	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00175	0.00213	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00175	0.00213	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00173	0.00211	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00173	0.0021	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00173	0.0021	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00172	0.00209	CbGpPWpGaD
Cevimeline—CHRM1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00171	0.00208	CbGpPWpGaD
Cevimeline—CHRM3—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.0017	0.00207	CbGpPWpGaD
Cevimeline—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00164	0.002	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00161	0.00196	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00161	0.00196	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—COMT—attention deficit hyperactivity disorder	0.00155	0.00188	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00153	0.00187	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00153	0.00186	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00152	0.00185	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00151	0.00184	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.0015	0.00183	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00144	0.00175	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00143	0.00174	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00141	0.00171	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.0014	0.00171	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.0014	0.00171	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.0014	0.0017	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00136	0.00165	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00135	0.00165	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00134	0.00163	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00134	0.00162	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00133	0.00162	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00133	0.00162	CbGpPWpGaD
Cevimeline—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00133	0.00161	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00132	0.0016	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00132	0.0016	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00132	0.0016	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00132	0.0016	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00131	0.00159	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.0013	0.00158	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00128	0.00156	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00127	0.00155	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00123	0.0015	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00123	0.00149	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00115	0.0014	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00115	0.00139	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00113	0.00138	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00113	0.00137	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000976	0.00119	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000973	0.00118	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000919	0.00112	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000897	0.00109	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000894	0.00109	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000886	0.00108	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000883	0.00107	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000879	0.00107	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000872	0.00106	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000867	0.00105	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000861	0.00105	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000858	0.00104	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	0.000854	0.00104	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000853	0.00104	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00085	0.00103	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000793	0.000965	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000791	0.000962	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000775	0.000942	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000772	0.000939	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000771	0.000938	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000768	0.000935	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000768	0.000934	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000766	0.000931	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000755	0.000919	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000755	0.000918	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000753	0.000916	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000753	0.000915	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000746	0.000907	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000743	0.000904	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000741	0.000901	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000738	0.000898	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00072	0.000876	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000718	0.000873	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000697	0.000848	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000695	0.000846	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000695	0.000845	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000692	0.000842	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000686	0.000834	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000683	0.000831	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000677	0.000824	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000675	0.000821	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000663	0.000806	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000634	0.000772	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000634	0.000772	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000631	0.000767	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000629	0.000765	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000624	0.000759	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00058	0.000706	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00055	0.000668	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000524	0.000637	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000522	0.000635	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000507	0.000617	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000486	0.000592	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000485	0.00059	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000483	0.000587	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000458	0.000557	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000456	0.000555	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000442	0.000537	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00044	0.000536	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000425	0.000517	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000424	0.000516	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000412	0.000501	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000411	0.0005	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000405	0.000493	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000404	0.000491	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.0004	0.000487	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000399	0.000485	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—COMT—attention deficit hyperactivity disorder	0.000384	0.000468	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000382	0.000464	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000379	0.000461	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000379	0.000461	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000373	0.000454	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000373	0.000453	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000371	0.000452	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000359	0.000437	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000347	0.000422	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000303	0.000369	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000289	0.000351	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000261	0.000317	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00026	0.000316	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000248	0.000302	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000248	0.000302	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000244	0.000297	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	0.00023	0.00028	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000228	0.000278	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000227	0.000276	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000198	0.000241	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000189	0.00023	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—EP300—attention deficit hyperactivity disorder	0.000165	0.0002	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	0.00015	0.000183	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000149	0.000181	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000138	0.000168	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000138	0.000168	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	9.86e-05	0.00012	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	6.44e-05	7.84e-05	CbGpPWpGaD
